Filing Details

Accession Number:
0001415889-24-029694
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-12-18 08:27:36
Reporting Period:
2024-12-17
Accepted Time:
2024-12-18 08:27:36
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1719406 Nrx Pharmaceuticals Inc. NRXP () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1303782 C Jonathan Javitt C/O Nrx Pharmaceuticals, Inc.
1201 Orange Street, Suite 600
Wilmington DE 19801
Chairman And Chief Scientist No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2024-12-17 40,000 $1.17 84,634 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 1,260,000 Indirect By the Jonathan Javitt Living Trust
Common Stock 142,200 Indirect By the Javitt 2012 Irrevocable Dynasty Trust
Common Stock 30,000 Indirect By the Jonathan Javitt Donor Advised Fund
Footnotes
  1. Held by the Jonathan Javitt Living Trust of which the reporting person is the trustee.
  2. Held by the Javitt 2012 Irrevocable Dynasty Trust of which the reporting person is the grantor of such trust. The reporting person is not a trustee or beneficiary of the Trust, and no beneficiary of the Trust resides in the reporting person's household. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
  3. Held by the Jonathan Javitt Donor Advised Fund of which the reporting person is the primary advisor of such fund.